Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Modulating the pathogenic potential of the group A Streptococcus

Award Number: R21AI139400
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 06/11/2018
PERIOD OF PERFORMANCE END DATE: 05/31/2021

Group Awards By:

View Award Description

Modulating the pathogenic potential of the group A Streptococcus - PROJECT SUMMARY The group A Streptococcus (GAS, S. pyogenes) causes ~700 million human infections annually. Perhaps the most important regulatory proteins in this bacterium are the control of virulence regulator (CovR) and sensor (CovS), which together form a two-component system (TCS). CovR/S potentiate the ability of GAS to cause non-invasive infections (e.g. pharyngitis), but this activity comes at the expense of invasive infection (e.g. necrotizing fasciitis) virulence. Importantly, covR or covS mutant strains are selected for during invasive GAS infections, creating hyper-virulent isolates. Despite the importance of CovR/S to GAS pathogenesis there remain significant gaps in our knowledge: (a) almost two decades have passed since the finding that covR and covS mutant strains are not equivalent, with the most striking difference being the levels of mRNA encoding for the secreted protease SpeB (a several thousand-fold difference); (b) the accessory protein regulator of cov (RocA) is a major activator of CovR activity, but the mechanism by which it does this is unknown; and (c) while rocA mutants can be recovered in a strain-specific manner from invasive infections, similar to the isolation of covR or covS mutants, a unique aspect of rocA is that certain GAS serotypes are exclusively rocA mutant, consistent with the regulatory and disease-phenotype consequences of losing RocA activity being distinct from losing CovR or CovS activity. The goals of this proposal are to provide a molecular explanation for why we observe regulatory disparity between these naturally-occurring GAS derivatives, to identify the virulence consequences of this disparity, and to determine how the regulatory components interact. In Aim 1 we will delineate physical and functional interactions between RocA and CovS. Preliminary data are consistent with the hypothesis that RocA complexes with CovS to enhance CovS kinase activity towards CovR. We will test the requirement of CovS kinase and phosphatase activities for RocA-mediated regulation after creating covS mutant GAS strains deficient in individual activities. We will also use two approaches to identify interactions between RocA and the CovS or CovR proteins. In Aim 2 we will determine the virulence characteristics of parental and naturally-occurring GAS variants, and the molecular basis of observed regulatory disparity between these isolates. Genome-wide approaches will be used to test the hypothesis that CovR~P and non-phosphorylated CovR have repressor activity, and that they target different subsets of CovR/S-repressed genes. To characterize how some GAS serotypes can tolerate being exclusively rocA mutant we will use ex vivo and in vivo models of infection, testing the hypothesis that rocA mutation, but not covR or covS mutation, only minimally impacts the ability of GAS to cause upper respiratory tract infections. Completing the proposed research will generate insights into why GAS variants are recovered in clinically- significant numbers, will generate the first mechanistic data for a TCS-regulating accessory protein from a Lactobacillale pathogen, and will answer a long-standing question in the field of streptococcal gene regulation.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2022 ( Subtotal = -$8,701 )
2022	2019	NEVADA SYSTEM OF HIGHER EDUCATION	1664 N VIRGINIA ST	RENO	NV	89557	WASHOE	USA	Allergy and Infectious Diseases Research	000	2	12/28/2021	NON-COMPETING CONTINUATION	-$8,701
														Subtotal = -$8,701

Issue Date FY: 2019 ( Subtotal = $214,271 )
2019	2019	NEVADA SYSTEM OF HIGHER EDUCATION	1664 N VIRGINIA ST	RENO	NV	89557	WASHOE	USA	Allergy and Infectious Diseases Research	000	2	5/10/2019	NON-COMPETING CONTINUATION	$214,271
														Subtotal = $214,271

Issue Date FY: 2018 ( Subtotal = $178,271 )
2018	2018	NEVADA SYSTEM OF HIGHER EDUCATION	1664 N VIRGINIA ST	RENO	NV	89557	WASHOE	USA	Allergy and Infectious Diseases Research	000	1	6/11/2018	NEW	$178,271
														Subtotal = $178,271

Grand Total All Awards = $383,841

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Modulating the pathogenic potential of the group A Streptococcus

Award Number: R21AI139400

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 06/11/2018

PERIOD OF PERFORMANCE END DATE: 05/31/2021

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer